Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

facility under the Credit Agreement from $50 million to $80 million.

Third Quarter Fiscal Year 2013 OutlookThe results of Oclaro for the third quarter of fiscal 2013, which ends March 30, 2013, are expected to be:

  • Revenues in the range of $140 million to $155 million.
  • Non-GAAP gross margin in the range of 10% to 14%.
  • Adjusted EBITDA in the range of negative $25 million to negative $13.5 million.
  • The foregoing guidance is based on current expectations. These statements are forward looking, and actual results may differ materially. Please see the Safe Harbor Statement in this earnings release for a description of certain important risk factors that could cause actual results to differ, and refer to Oclaro's most recent annual and quarterly reports on file with the Securities and Exchange Commission (SEC) for a more complete description of these risks. Furthermore, our outlook excludes items that may be required by GAAP, including, but not limited to, restructuring and related costs, acquisition or disposal related costs, any additional flood-related expenses, expenses or income from certain legal actions, settlements and related costs outside our normal course of business, impairments of other long-lived assets, depreciation and amortization, extraordinary items, as well as the expensing of stock options and restricted stock grants. We do not intend to update this guidance as a result of developments occurring after the date of this release.

    Conference CallOclaro will hold a conference call to discuss financial results for the second quarter of fiscal 2013 today at 1:30 p.m. PT/4:30 p.m. ET. To listen to the live conference call, please dial (480) 629-9665. A replay of the conference call will be available through February 7, 2013. To access the replay, dial (858) 384-5517. The passcode for the replay is 4593179. A webcast of this call and a supplemental presentation will be available in the investor sec
    '/>"/>

    SOURCE Oclaro, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
    2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
    4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
    5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
    6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
    7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
    8. Kemwell Announces Successful Pre-NDA US FDA Inspection
    9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
    10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
    11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today announced validation by ... Authorization Application (MAA) for sebelipase alfa for LAL ... for accelerated assessment, which has the potential to ... The MAA, and the Biologics License Application ...
    (Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning ... of Lockton Companies, announced the addition of Vice ... will join Lockton Dunning,s Pharmacy Consulting team, Excelsior ... of relevant industry experience to the position.  Most ... Market Sales at Diplomat Specialty Pharmacy, where she ...
    (Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
    Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
    ... Oct. 27 According to Millennium Research Group ... intelligence, the European arthroscope market generated over $30 ... over 2009 due to decreasing scope prices and ... Due to unfavorable economic conditions, manufacturers are ...
    ... today announced that it has received approval from the ... (US 7,815,929) regarding a method for the preparation, storage ... very nature, the process of compounding suppositories is cumbersome, ... Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. ...
    Cached Medicine Technology:Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 2Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 3CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding 2
    (Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
    (Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
    (Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
    (Date:12/25/2014)... December 25, 2014 Helen Harris’ RP ... Woodland Hills, California after an 8 year battle with ... Christmas Eve evening in her home in Woodland Hills ... breast cancer. , As the founder ... years, she pioneered and championed many of today's greatest ...
    (Date:12/25/2014)... -- The risk of burns from fires and cooking ... be extra cautious, an expert says. "Between Thanksgiving ... in patients coming in with burns," said Dr. Steven ... Burn Center of Stony Brook University Hospital in New ... but if not careful, could quickly turn tragic," Sandoval ...
    Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2
    ... anesthetics are most commonly used for cosmetic procedures and to ... as lidocaine, tetracaine, benzocaine, and prilocaine in a cream, ointment, ... products can cause serious and life-threatening side effects such as ... stop breathing. ,According to the FDA the ...
    ... condition called nephrogenic systemic fibrosis (NSF)— which occurs only ... use of gadolinium dyes for MRI scans, reports a ... Society of Nephrology. ,An accompanying editorial identifies ... be avoided, at least until more information is available. ...
    ... in two cases, greater than $100,000 -- by people without ... a class of drugs commonly used to treat the neurological ... is the first to describe this compulsive gambling in RLS ... receptors in the brain. ,The extent of this ...
    ... relying on beauticians and barbers to spread awareness of ... ,What they can do may be as vital as ... slated for presentation this week at the American Stroke ... ideal place to educate minority women about strokes. ...
    ... decided to appoint ayurveda, homeopathy and unani doctors without ... interview. ,Clearing the way for the ... decided that the government would advertise for the posts ... ,The interviews would be held at the division level. ...
    ... beneficial, standardized recommendations for public health.// ... Mayer USDA Human Nutrition Research on Aging (USDA ... Supplements and Chronic Disease Prevention,” outlines challenges and ... and minerals. ,"The evidence regarding vitamin ...
    Cached Medicine News:Health News:FDA Warns of Deadly Results of Skin-numbing Creams 2Health News:MRI Contrast Agent Linked to Complication in Renal Patients 2Health News:Medications for Restless Legs Syndrome may Trigger Compulsive Gambling 2Health News:Medications for Restless Legs Syndrome may Trigger Compulsive Gambling 3Health News:Beauticians and Barbers can Do More Than Their Services 2Health News:Effective Marketing of Multivitamins Essential 2
    High temp cauteries, fine tip micro....
    Thru cut kerrison style punch 30 deg, 2.75 X 1.4 mm cut, 110 working length....
    6 mm, 45 degree upwards, detachable....
    Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
    Medicine Products: